BioSpace News Archive

Kalos Medical, Inc. announced that on April 24th it was selected as a participant in the 2023 Industrial Technology Innovation Project, administered by South Korea’s Ministry of Trade, Industry, and Energy.

The Bristol Myers Squibb Trauma Center at Capital Health Regional Medical Center has been recertified as a Level II Trauma Center by the Committee on Trauma of the American College of Surgeons.

HuidaGene Therapeutics today announced nineteen (19) presentations on Company’s various gene replacement and gene-editing platforms to unlock the full potential of genome medicines at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place in Los Angeles from May 16-20, 2023.

PharmaEssentia USA Corporation today announced that the first patients are now being dosed in ECLIPSE PV, a Phase 3b clinical study evaluating an accelerated dosing schedule for ropeginterferon alfa-2b-njft using a prefilled syringe for the treatment of adults with polycythemia vera (PV).

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report.

Gate Neurosciences announced it has increased its R&D capabilities with new expanded research operations and lab facilities in Evanston, Illinois.

EvoEndo®, Inc. (“EvoEndo”), a medical device company developing platforms for Unsedated Transnasal Endoscopy (TNE), is proud to announce that David Pierce has joined our Board of Directors.

Apertura Gene Therapy today announced that academic collaborator and scientific co-founder, Ben Deverman, PhD, Senior Director of Vector Engineering and Institute Scientist at the Broad Institute of MIT and Harvard, will present at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).

Pulse Biosciences, Inc. today announced the appointment of Gansevoort “Gan” Dunnington, M.D. as its Chief Medical Officer.

Inozyme Pharma, Inc. announced that the Company granted stock options to new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.